Please login to the form below
risankizumab
This page shows the latest risankizumab news and features for those working in and with pharma, biotech and healthcare.
CHMP backs Lynparza in breast cancer, Dupixent in asthma
AbbVie and Boehringer Ingelheim’s IL-23 inhibitor Skyrizi (risankizumab) for the treatment of moderate to severe psoriasis.
Latest news
-
AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod
Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading future development and commercialisation of the drug globally. ... Risankizumab is also being in clinical trials for a number of other inflammatory
-
European biosimilars hit AbbVie’s Humira revenues in Q4
Meanwhile another blockbuster hopeful, risankizumab was filed last year for moderate to severe plaque psoriasis, with FDA approval expected in April.
-
New data keeps AbbVie’s star pipeline therapies on track
Data showed 56% of patients on risankizumab were symptom free after a year’s treatment. ... The analysis showed that 56% of patients on risankizumab were symptom-free after a year’s treatment, compared to 30% of the Stelara group.
-
BMS psoriasis drug hits the mark in phase II
including Johnson &Johnson’s Stelara (ustekinumab) and follow-up Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie’s recently-filed risankizumab.
-
Boehringer beefs up biologics capacity with €230m investment
That includes its portfolio of biosimilar drugs, as well as novel candidates such as AbbVie-partnered interleukin-23 inhibitor risankizumab – in phase III trials in psoriasis and psoriatic arthritis – and
More from news
Approximately 3 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
It announced the filing of upadacitinib in the US and Europe on 20 December, with the filing of risankizumab expected early this year. ... The analysis showed that 56% of patients on risankizumab were symptom-free after a year’s treatment, compared to
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Senior Account Manager, Medical Communications, London
-
Excellent package
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
-
Senior Medical Writer
-
Salary TBC
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
- Scientific Director – Medical Communications
-
Salary TBC
- Associate Director – Social Healthcare – London
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Health Consultant - Brand Comms
-
Competitive Salary
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
-
Account Director, Medical Education
-
Salary TBC
Subscribe to our email news alerts
PMHub
Syneos Health™
Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...
Latest intelligence
- 50 questions for delivering an exceptional healthcare brand experience
- Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
- The brand strategy revolution
- Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Quick links
Infographics
